Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 387 results for "pfizer"

Botox plant to stay in Mayo
Irish Independent

Botox plant to stay in Mayo

ACTAVIS has warned that rival Pfizer will struggle to find uses for its large Lipitor-producing facilities in Cork, while affirming its commitment to Ireland after the purchase of Botox-maker Allergan. ACTAVIS has warned that rival Pfizer will ... Irish Independent, 16 hours ago

302 images for pfizer

WKRB News, 8 hours ago
Salt N Peppa, 10 hours ago
Salt N Peppa, 10 hours ago
Philanthropy News Digest, 4 days ago
One News Page United Kingdom, 2 days ago
CTV News, 5 days ago
Irish Times, 6 days ago
Fidelity Brokerage Services LLC, 6 days ago
Investing.com, 6 days ago
Pharmafocus, 5 days ago

UK drugmakers back in spotlight as bidders free to return

Restrictions on Pfizer and Stryker reviving their bid interest in AstraZeneca and Smith & Nephew will expire
 Yahoo! UK and Ireland22 hours ago
Citybizlist

Merck Collaboration Rules Out AstraZeneca Acquisition--For Now

Summary Pfizer's multi-billion dollar agreement with Merck excludes either drugmaker from collaborating with other companies on the drug. This class of drugs happens to be one of AstraZeneca's main focuses. The collaboration is a risk for Pfizer, ...
 Seeking Alpha1 day ago Cramer: Pfizer Deal With Merck Leaves AstraZeneca In the Cold  TheStreet.com6 days ago Pfizer ends Astra bid hopes with Merck deal  Irish Examiner5 days ago Pfizer signs deal with Merck  The Gulf Today5 days ago
[x]  
Bidness Etc

Weekly Pharmaceutical Notes: Pfizer, Johnson & Johnson, Bristol-Myers Squibb And Roche

It was a week of new approvals, cancer drug deals and promising clinical trials for big pharmaceutical companies. However their shares, as a whole, did not move significantly and mostly traded in range. While Pfizer (NYSE:PFE) signed a research deal ...
 Trefis2 days ago Pfizer/Merck KGaA Immune Checkpoint Deal Bodes Extremely Well For Compugen  Seeking Alpha2 days ago Merck forms global alliance with Pfizer for co- developing cancer drug  Business Standard4 days ago Pfizer Inc. (PFE) Strikes $2.85 Billion Deal With Merck KGaA To Co-Develop Cancer Immunotherapy Drug  Bidness Etc5 days ago
[x]  

Pfizer : Releases Trumenba

Pfizer reported that Trumenba (Meningococcal Group B Vaccine), the first and only FDA -approved vaccine for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age, is ...
 4 Traders1 day ago Pfizer Releases Trumenba  Individual.com2 days ago Pfizer announces availability of first US FDA approved TRUMENBA (Meningococcal Group B Vaccine) in the US  Individual.com4 days ago Pfizer Announces U.S. Availability Of TRUMENBA  RTTNews.com5 days ago
Fortune

Sloan: 2014's biggest financial turkey? Pfizer's bungled attempt to gobble up AstraZeneca.

By , Thanksgiving, the quintessential American holiday, is almost upon us. That makes this an absolutely perfect time to talk about turkeys — of the financial variety, of course. We have an unusually plentiful flock this year, featuring giant ...
 Washington Post2 days ago Apple, Pfizer, GM and other financial turkeys of 2014  Fortune3 days ago
Bioresearch Online

Pfizer Links With Merck KGaA In Immuno-Oncology Mega Deal

By Estel Grace Masangkay Pfizer announced that it has signed up with German firm Merck KGaA to co-develop and market an investigational anti-PD-L1 treatment for several types of cancer. As part of the agreement, Pfizer will pay Merck KGaA ...
 Bioresearch Online4 days ago Merck KGaA Ties Up with Pfizer on Immuno-oncology Deal  Yahoo! Finance4 days ago Pfizer aligns with Merck KGaA in oncology  MedNous4 days ago AstraZeneca's anti-Pfizer growth promises? At least one big investor is buying  FiercePharma5 days ago
[x]  
Pharmaceutical Business Review

Pfizer, Merck ink agreement to jointly develop anti-PD-L1 to accelerate presence in immuno-oncology

Pfizer has entered into an agreement with Merck KGaA, Darmstadt, Germany, to jointly develop and commercialise MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck KGaA as a potential treatment for multiple types of ...
 PharmaBiz4 days ago Pfizer and Merck KGaA, Germany, to Develop Cancer Treatments  Pharmaceutical Manufacturing Magazine4 days ago Pfizer, Germany's Merck KgaA Collaborate To Develop Cancer Drug - Update  RTTNews.com6 days ago Pfizer, Merck KGaA Partner To Develop & Commercialize Anti-PD-L1 - Quick Facts  RTTNews.com6 days ago
Pharmafocus

Pfizer Is Set to Buy Merck Cancer Drug Rights for $850 Million

Dividend Stock Advisor Try it NOW Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream. Product Features: Diversified model ...
 TheStreet.com6 days ago Pfizer signs $3 billion cancer deal  Pharmafocus5 days ago Pfizer Cancer Pact With Merck May Show Waning Astra Pursuit  Washington Post6 days ago Pfizer will pay $850m for rights to Merck cancer drug  Irish Times6 days ago
[x]  

Pfizer (PFE) Trading Near $30.71 Resistance Level

Pfizer Inc. (http://www.marketintelligencecenter.com/symbol/PFE"PFE) was selected by MarketIntelligenceCenter.comaEUR(TM)s trade-picking algorithms today after trading between $30.28 and $30.56 on Wednesday before closing at $30.44. A diagonal ...
 Individual.com2 days ago Pfizer (PFE) Trading Near $30.03 Support Level  Individual.com6 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less